Overview

Outpatient Vasodilator Assessment Using Iloprost in Pulmonary Hypertension

Status:
Recruiting

Trial end date:
2022-12-01

Target enrollment:
0

Participant gender:
All

Summary

This study will compare the clinical efficacy of inhaled iloprost as an invasive, selective vasodilator in the cardiac catheterization laboratory in patients with pulmonary hypertension to the gold standard of inhaled nitric oxide. It will also examine whether echocardiographic estimates of response to inhaled iloprost can predict responsiveness to invasive vasodilator testing in patients with pulmonary hypertension.

Phase:

Phase 4

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Duke University

Collaborator:

Actelion

Treatments:

Iloprost
Nitric Oxide
Vasodilator Agents

Criteria

Inclusion Criteria:

- Adult patients no younger than 18 years of age

- Recently diagnosed pulmonary hypertension (defined by RV systolic pressure of ≥ 40
mmHg as measured by echocardiography), going for invasive hemodynamic assessment for
pulmonary hypertension

- Normal left ventricular function defined as a left ventricular ejection fraction
(LVEF) greater than or equal to 50%

Exclusion Criteria:

- Heart failure (LVEF < 50%, diastolic dysfunction > stage 1, history or symptoms of
left heart failure) - Group II pulmonary hypertension

- 2+ or higher MR or AI

- Inadequate echocardiographic windows

- Pregnancy

- Systolic blood pressure ≤ 90 mmHg